PriceTargets.com logo

NASDAQ:APEN - Apollo Endosurgery Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.33
  • Forecasted Upside: 53.79 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$9.32 As of 09/24/2021 01:00 AM ET
▲ +0.12 (1.30%)

This chart shows the closing price for APEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Apollo Endosurgery Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APEN

Analyst Price Target is $14.33
▲ +53.79% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Apollo Endosurgery in the last 3 months. The average price target is $14.33, with a high forecast of $15.00 and a low forecast of $14.00. The average price target represents a 53.79% upside from the last price of $9.32.

This chart shows the closing price for APEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Apollo Endosurgery. This rating has held steady since December 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2021StephensInitiated CoverageOverweight$15.00Medium
8/4/2021Lake Street CapitalBoost Price TargetBuy$12.00 ➝ $14.00High
8/4/2021Piper SandlerBoost Price TargetOverweight$11.00 ➝ $14.00High
6/14/2021Piper SandlerBoost Price TargetOverweight$9.00 ➝ $11.00Medium
5/24/2021Piper SandlerBoost Price TargetPositive ➝ Overweight$8.50 ➝ $9.00Medium
5/17/2021Lake Street CapitalInitiated CoverageBuy$12.00High
3/22/2021Piper SandlerBoost Price Target$7.00 ➝ $8.00Low
11/30/2020Piper SandlerUpgradeNeutral ➝ Overweight$2.00 ➝ $5.00High
4/28/2020Piper SandlerDowngradeOverweight ➝ Neutral$4.50 ➝ $2.00Medium
3/27/2020Piper SandlerLower Price TargetOverweight$5.50 ➝ $4.50Low
1/2/2019Northland SecuritiesUpgradeUnder Perform ➝ Market Perform$3.00High
11/12/2018Roth CapitalSet Price TargetHold$4.00Low
11/9/2018Northland SecuritiesDowngradeMarket Perform ➝ Under Perform$7.00 ➝ $3.00High
8/9/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformHigh
7/17/2018Roth CapitalReiterated RatingBuy ➝ Neutral$9.50Low
4/13/2018Piper Jaffray CompaniesInitiated CoverageOverweight$8.00Medium
2/8/2018Northland SecuritiesReiterated RatingBuy$12.00Low
1/4/2018Roth CapitalSet Price TargetBuy ➝ Buy$10.00High
12/4/2017Northland SecuritiesReiterated RatingBuy$12.00Low
11/28/2017Northland SecuritiesReiterated RatingBuy$12.00Medium
10/27/2017Northland SecuritiesReiterated RatingBuyN/A
9/26/2017Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$12.00Low
8/2/2017Roth CapitalInitiated CoverageBuy ➝ Buy$10.00Medium
7/24/2017Craig HallumInitiated CoverageBuy$11.00High
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2021

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Apollo Endosurgery logo
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, OverStitch Sx Endoscopic Suturing System, and Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon; the treatment of swallowing disorders; esophageal stent fixation and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $9.32
Low: $9.19
High: $9.64

50 Day Range

MA: $8.68
Low: $7.35
High: $9.93

52 Week Range

Now: $9.32
Low: $1.38
High: $10.04

Volume

217,600 shs

Average Volume

396,249 shs

Market Capitalization

$267.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Apollo Endosurgery?

The following Wall Street research analysts have issued reports on Apollo Endosurgery in the last year: Lake Street Capital, Piper Sandler, Stephens, and Zacks Investment Research.
View the latest analyst ratings for APEN.

What is the current price target for Apollo Endosurgery?

3 Wall Street analysts have set twelve-month price targets for Apollo Endosurgery in the last year. Their average twelve-month price target is $14.33, suggesting a possible upside of 53.8%. Stephens has the highest price target set, predicting APEN will reach $15.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $14.00 for Apollo Endosurgery in the next year.
View the latest price targets for APEN.

What is the current consensus analyst rating for Apollo Endosurgery?

Apollo Endosurgery currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APEN will outperform the market and that investors should add to their positions of Apollo Endosurgery.
View the latest ratings for APEN.

What other companies compete with Apollo Endosurgery?

Other companies that are similar to Apollo Endosurgery include AngioDynamics, CryoLife, Intersect ENT, Tactile Systems Technology, Longview Acquisition Corp. II, Bioventus, OraSure Technologies, PAVmed, SI-BONE, Surmodics, Orthofix Medical, Nyxoah, MiMedx Group, Pulse Biosciences and Vapotherm.

How do I contact Apollo Endosurgery's investor relations team?

Apollo Endosurgery's physical mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company's listed phone number is (512) 279-5100 and its investor relations email address is [email protected] The official website for Apollo Endosurgery is www.apolloendo.com.